Yahya, E. B.; Alqadhi, A. M. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sci. 2021 , 269 , 119087..

Zhang, Y.; Zhang, W.; Wang, Y.; Zhu, J.; Zhou, M.; Peng, C.; He, Z.; Sun, J.; Li, Z.; Gui, S. Emerging nanotaxanes for cancer therapy. Biomaterials 2021 , 272 , 120790..

Aldonza, M. B. D.; Ku, J.; Hong, J.-Y.; Kim, D.; Yu, S. J.; Lee, M.-S.; Prayogo, S. T. M. C.; Kim, D.; Han, J.; Lee, S. K.; Im, S. G.; Ryu, H. S.; Kim, Y. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Sci. Adv. 2020 , 6 , eaav7416..

Chen, Q.; Sun, T.; Jiang, C. Recent advancements in nanomedicine for 'cold' tumor immunotherapy. Nanomicro Lett. 2021 , 13 , 92..

Jahanban-Esfahlan, R.; Seidi, K.; Monhemi, H.; Adli, A. D. F.; Minofar, B.; Zare, P.; Farajzadeh, D.; Farajnia, S.; Behzadi, R.; Abbasi, M. M.; Zarghami, N.; Javaheri, T. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice. Sci. Rep. 2017 , 7 , 8126..

Baghban, R.; Roshangar, L.; Jahanban-Esfahlan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Zare, P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020 , 18 , 59..

Binnewies, M.; Roberts, E. W.; Kersten, K.; Chan, V.; Fearon, D. F.; Merad, M.; Coussens, L. M.; Gabrilovich, D. I.; Ostrand-Rosenberg, S.; Hedrick, C. C.; Vonderheide, R. H.; Pittet, M. J.; Jain, R. K.; Zou, W.; Howcroft, T. K.; Woodhouse, E. C.; Weinberg, R. A.; Krummel, M. F. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018 , 24 , 541−550..

Li, X.; Yang, Y.; Huang, Q.; Deng, Y.; Guo, F.; Wang, G.; Liu, M. Crosstalk between the tumor microenvironment and cancer cells: A promising predictive biomarker for immune checkpoint inhibitors. Front. Cell Dev. Biol. 2021 , 9 , 738373..

Henke, E.; Nandigama, R.; Ergun, S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front. Mol. Biosci. 2019 , 6 , 160..

Muntimadugu, E.; Kommineni, N.; Khan, W. Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol. Res. 2017 , 126 , 109−122..

Ding, J.; Chen, J.; Gao, L.; Jiang, Z.; Zhang, Y.; Li, M.; Xiao, Q.; Lee, S. S.; Chen, X. Engineered nanomedicines with enhanced tumor penetration. Nano Today 2019 , 29 , 100800..

Min, Y.; Caster, J. M.; Eblan, M. J.; Wang, A. Z. Clinical translation of nanomedicine. Chem. Rev. 2015 , 115 , 11147−11190..

Oberoi, P.; Jabulowsky, R. A.; Bahr-Mahmud, H.; Wels, W. S. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 2013 , 8 , e61267..

Chi, L. H.; Cross, R. S. N.; Redvers, R. P.; Davis, M.; Hediyeh-Zadeh, S.; Mathivanan, S.; Samuel, M.; Lucas, E. C.; Mouchemore, K.; Gregory, P. A.; Johnstone, C. N.; Anderson, R. L. MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. Oncogenesis 2022 , 11 , 38..

Bautista-Sanchez, D.; Arriaga-Canon, C.; Pedroza-Torres, A.; De La Rosa-Velazquez, I. A.; Gonzalez-Barrios, R.; Contreras-Espinosa, L.; Montiel-Manriquez, R.; Castro-Hernandez, C.; Fragoso-Ontiveros, V.; Alvarez-Gomez, R. M.; Herrera, L. A. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol. Ther. Nucleic Acids 2020 , 20 , 409−420..

Perez-Tomas, R.; Perez-Guillen, I. Lactate in the tumor microenvironment: An essential molecule in cancer progression and treatment. Cancers (Basel) 2020 , 12 , 3244..

Ozga, A. J.; Chow, M. T.; Luster, A. D. Chemokines and the immune response to cancer. Immunity 2021 , 54 , 859−874..

Domagala, J.; Lachota, M.; Klopotowska, M.; Graczyk-Jarzynka, A.; Domagala, A.; Zhylko, A.; Soroczynska, K.; Winiarska, M. The tumor microenvironment-a metabolic obstacle to NK cells' activity. Cancers (Basel) 2020 , 12 , 3542..

Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017 , 387 , 61−68..

Vinogradov, S.; Warren, G.; Wei, X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (Lond.) 2014 , 9 , 695−707..

Pal, S.; Nandi, M.; Dey, D.; Chakraborty, B. C.; Shil, A.; Ghosh, S.; Banerjee, S.; Santra, A.; Ahammed, S. K. M.; Chowdhury, A.; Datta, S. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment. Pharmacol. Ther. 2019 , 49 , 1346−1359..

Lichtnekert, J.; Kawakami, T.; Parks, W. C.; Duffield, J. S. Changes in macrophage phenotype as the immune response evolves. Curr. Opin. Pharmacol. 2013 , 13 , 555−564..

Atri, C.; Guerfali, F. Z.; Laouini, D. Role of human macrophage polarization in inflammation during infectious diseases. Int. J. Mol. Sci. 2018 , 19 , 1801..

Ma, Z.; Yang, M.; Foda, M. F.; Zhang, K.; Li, S.; Liang, H.; Zhao, Y.; Han, H. Polarization of tumor-associated macrophages promoted by vitamin c-loaded liposomes for cancer immunotherapy. ACS Nano 2022 , 16 , 17389−17401..

Cao, M.; Yan, H.; Han, X.; Weng, L.; Wei, Q.; Sun, X.; Lu, W.; Wei, Q.; Ye, J.; Cai, X.; Hu, C.; Yin, X.; Cao, P. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J. Immunother. Cancer 2019 , 7 , 326..

Ye, C.; Yan, X.; Dai, X.; Chen, R.; Li, Q.; Xu, S.; Jiang, Q.; Yan, F.; Xu, S.; Zhao, C.-X.; Zhao, P.; Chen, D.; Ruan, J. Biocompatible snowman-like tumor-targeting dimer nanoparticles for improved delivery efficiency and enhanced anti-tumor therapy. Chem. Eng. J. 2023 , 474 , 145766..

Jiang, M.; Qi, Y.; Huang, W.; Lin, Y.; Li, B. Curcumin reprograms TAMs from a protumor phenotype towards an antitumor phenotype via inhibiting MAO-A/STAT6 pathway. Cells 2022 , 11 , 3473..

Zhang, Y.; Feng, Z.; Liu, J.; Li, H.; Su, Q.; Zhang, J.; Huang, P.; Wang, W.; Liu, J. Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance. Bioact. Mater. 2022 , 16 , 359−371..

Figueiredo, P.; Lepland, A.; Scodeller, P.; Fontana, F.; Torrieri, G.; Tiboni, M.; Shahbazi, M. A.; Casettari, L.; Kostiainen,M. A.; Hirvonen, J.; Teesalu, T.; Santos, H. A. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomater. 2021 , 133 , 231−243..

Wang, Y.; Li, G.; Su, J.; Liu, Y.; Zhang, X.; Zhang, G.; Wu, Z.; Li, J.; Wang, X.; Zhang, Y.; Bai, M.; Yao, Y.; Wang, R.; Shao, K. Tumor-associated macrophages nano-reprogrammers induce “gear effect” to empower glioblastoma immunotherapy. Small 2025 , 21 , 2406839..

Schnell, A.; Bod, L.; Madi, A.; Kuchroo, V. K. The yin and yang of co-inhibitory receptors:Toward anti-tumor immunity without autoimmunity. Cell Res. 2020 , 30 , 285−299..

Song, M.; Liu, T.; Shi, C.; Zhang, X.; Chen, X. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano 2016 , 10 , 633−647..

Qiu, N.; Wang, G.; Wang, J.; Zhou, Q.; Guo, M.; Wang, Y.; Hu, X.; Zhou, H.; Bai, R.; You, M.; Zhang, Z.; Chen, C.; Liu, Y.; Shen, Y. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient interleukin-12 cancer gene therapy. Adv. Mater. 2021 , 33 , e2006189..

Zhang, F.; Parayath, N. N.; Ene, C. I.; Stephan, S. B.; Koehne, A. L.; Coon, M. E.; Holland, E. C.; Stephan, M. T. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 2019 , 10 , 3974..

Li, Y.; Su, Z.; Zhao, W.; Zhang, X.; Momin, N.; Zhang, C.; Wittrup, K. D.; Dong, Y.; Irvine, D. J.; Weiss, R. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat. Cancer 2020 , 1 , 882−893..

Hollen, M. K.; Stortz, J. A.; Darden, D.; Dirain, M. L.; Na cionales, D. C.; Hawkins, R. B.; Cox, M. C.; Lopez, M. C.; Rincon, J. C.; Ungaro, R.; Wang, Z.; Wu, Q.; Brumback, B.; Gauthier, M. L.; Kladde, M.; Leeuwenburgh, C.; Segal, M.; Bihorac, A.; Brakenridge, S.; Moore, F. A.; Baker, H. V.; Mohr, A. M.; Moldawer, L. L.; Efron, P. A. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Crit. Care 2019 , 23 , 355..

Veglia, F.; Sanseviero, E.; Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021 , 21 , 485−498..

Lasser, S. A.; Ozbay Kurt, F. G.; Arkhypov, I.; Utikal, J.; Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 2024 , 21 , 147−164..

Law, A. M. K.; Valdes-Mora, F.; Gallego-Ortega, D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 2020 , 9 , 561..

Condamine, T.; Ramachandran, I.; Youn, J. I.; Gabrilovich, D. I. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 2015 , 66 , 97−110..

Dai, X.; Ren, L.; Liu, M.; Cai, H.; Zhang, H.; Gong, Q.; Gu, Z.; Luo, K. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today 2021 , 39 , 101163..

Zhang, Y.; Bush, X.; Yan, B.; Chen, J. A. Gemcitabine nanoparticles promote antitumor immunity against melanoma. Biomaterials 2019 , 189 , 48−59..

Liang, Y.; Wang, W.; Zhu, X.; Yu, M.; Zhou, C. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer. Sci. Rep. 2022 , 12 , 9619..

Varikuti, S.; Singh, B.; Volpedo, G.; Ahirwar, D. K.; Jha, B. K.; Saljoughian, N.; Viana, A. G.; Verma, C.; Hamza, O.; Halsey, G.; Holcomb, E. A.; Maryala, R. J.; Oghumu, S.; Ganju, R. K.; Satoskar, A. R. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. Br. J. Cancer 2020 , 122 , 1005−1013..

Qiu, Q.; Li, C.; Song, Y.; Shi, T.; Luo, X.; Zhang, H.; Hu, L.; Yan, X.; Zheng, H.; Liu, M.; Liu, M.; Liu, M.; Yang, S.; Liu, X.; Chen, G.; Deng, Y. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta Biomater. 2019 , 92 , 184−195..

Conniot, J.; Scomparin, A.; Peres, C.; Yeini, E.; Pozzi, S.; Matos, A. I.; Kleiner, R.; Moura, L. I. F.; Zupancic, E.; Viana, A. S.; Doron, H.; Gois, P. M. P.; Erez, N.; Jung, S.; Satchi-Fainaro, R.; Florindo, H. F. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 2019 , 14 , 891−901..

Li, S.; Wang, Q.; Shen, Y.; Hassan, M.;Shen, J.; Jiang, W.; Su, Y.; Chen, J.; Bai, L.; Zhou, W.; Wang, Y. Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy. Nano Lett. 2020 , 20 , 242−251..

Hammami, I.; Chen, J.; Murschel, F.; Bronte, V.; De Crescenzo, G.; Jolicoeur, M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells. BMC Cell Biol. 2012 , 13 , 18..

Ledo, A. M.; Sasso, M. S.; Bronte, V.; Marigo, I.; Boyd, B. J.; Garcia-Fuentes, M.; Alonso,M. J. Co-delivery of RNAi and chemokine by polyar ginine nanocapsules enables the modulation of myeloid-derived suppressor cells. J. Control. Release 2019 , 295 , 60−73..

Wang, H.; Franco, F.; Ho, P. C. Metabolic regulation of Tregs in cancer: Opportunities for immunotherapy. Trends Cancer 2017 , 3 , 583−592..

Dejaco, C.; Duftner, C.; Grubeck-Loebenstein, B.; Schirmer, M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006 , 117 , 289−300..

Traxinger, B. R.; Richert-Spuhler, L. E.; Lund, J. M. Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry. Mucosal Immunol. 2022 , 15 , 398−407..

Huppert, L. A.; Green, M. D.; Kim, L.; Chow, C.; Leyfman, Y.; Daud, A. I.; Lee, J. C. Tissue-specific Tregs in cancer metastasis: Opportunities for precision immunotherapy. Cell. Mol. Immunol. 2022 , 19 , 33−45..

Tekguc, M.; Wing, J. B.; Osaki, M.; Long, J.; Sakaguchi, S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-pres enting cells. Proc. Natl. Acad. Sci. U. S. A. 2021 , 118 , e2023739118..

Cheng, G.; Yu, A.; Malek, T. R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol. Rev. 2011 , 241 , 63−76..

Strauss, L.; Whiteside, T. L. Human circulating CD4+CD25high FOXP3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J. Immunol. 2009 , 182 , 1469−1480..

Shalev, I.; Schmelzle, M.; Robson, S. C.; Levy, G. Making sense of regulatory T cell suppressive function. Semin. Immunol. 2011 , 23 , 282−292..

Gonzalez-Navajas, J. M.; Fan, D. D.; Yang, S.; Yang, F. M.; Lozano-Ruiz, B.; Shen, L.; Lee, J. The impact of Tregs on the anticancer immunity and the efficacy of immune checkpoint inhibitor therapies. Front. Immunol. 2021 , 12 , 625783..

Barati, M.; Mirzavi, F.; Nikpoor, A. R.; Sankian, M.; Namdar Ahmadabad, H.; Soleimani, A.; Mashreghi, M.; Tavakol Afshar, J.; Mohammadi, M.; Jaafari, M. R. Enhanced antitumor immun e response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Ther. 2022 , 29 , 814−824..

Vignali, D. A.; Collison, L. W.; Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 2008 , 8 , 523−532..

Li, S. Y.; Liu, Y.; Xu, C. F.; Shen, S.; Sun, R.; Du, X. J.; Xia, J. X.; Zhu, Y. H.; Wang, J. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J. Control. Release 2016 , 231 , 17−28..

Tanaka, A.; Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. Eur. J. Immunol. 2019 , 49 , 1140−1146..

Ou, W.; Thapa, R. K.; Jiang, L.; Soe, Z. C.; Gautam, M.; Chang, J. H.; Jeong, J. H.; Ku, S. K.; Choi, H. G.; Yong, C. S.; Kim, J. O. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J. Control. Release 2018 , 281 , 84−96..

Facciabene, A.; Motz, G. T.; Coukos, G. T-regulatory cells: Key players in tumor imm une escape and angiogenesis. Cancer Res. 2012 , 72 , 2162−2171..

Kim, D.; Wu, Y.; Li, Q.; Oh, Y. K. Nanoparticle-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy. Nanomicro Lett. 2021 , 13 , 31..

Zhang, N.; Liu, S.; Shi, S.; Chen, Y.; Xu, F.; Wei, X.; Xu, Y. Solubilization and delivery of ursolic-acid for modulating tumor microenvironment and regulatory T cell activities in cancer immunotherapy. J. Control. Release 2020 , 320 , 168−178..

Wang, M.; Yan, D.; Wang, M.; Wu, Q.; Song, R.; Huang, Y.; Rao, J.; Wang, D.; Zhou, F.; Tang, B. Z. A versatile 980 nm absorbing aggregation-induced emission luminogen for NIR-II imaging-guided synergistic photo-immunotherapy against advanced pancreatic cancer. Adv. Funct. Mater. 2022 , 32 , 2205371..

He, S.; Li, J.; Cheng, P.; Zeng, Z.; Zhang, C.; Duan, H.; Pu, K. Charge-reversal polymer nano-modulators for photodynamic immunotherapy of cancer. Angew. Chem. Int. Ed. 2021 , 60 , 19355−19363..

Erdogan, B.; Webb, D. J. Cancer-associated fibroblasts modulate growth factor signalingand extracellular matrix remodeling to regulate tumor metastasis. Biochem. Soc. Trans. 2017 , 45 , 229−236..

Chen, Y.; Hu, M.; Wang, S.; Wang, Q.; Lu, H.; Wang, F.; Wang, L.; Peng, D.; Chen, W. Nano-delivery of salvianolic acid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-beta1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor. Int. J. Pharm. 2022 , 623 , 121953..

Cun, X.; Chen, J.; Li, M.; He, X.; Tang, X.; Guo, R.; Deng, M.; Li, M.; Zhang, Z.; He, Q. Tumor-associated fibroblast-targeted regulation and deep tumor delivery of chemotherapeutic drugs with a multifunctional size-switchable nanoparticle. ACS Appl. Mater. Interfaces 2019 , 11 , 39545−39559..

Hu, K.; Miao, L.; Goodwin, T. J.; Li, J.; Liu, Q.; Huang, L. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano 2017 , 11 , 4916−4925..

Munir, M. U. Nanomedicine penetration to tumor: Challenges, and advanced strategies to tackle this issue. Cancers (Basel) 2022 , 14 , 2904..

Khawar, I. A.; Kim, J. H.; Kuh, H. J. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J. Control. Release 2015 , 201 , 78−89..

Li, L.; Zhou, S.; Lv, N.; Zhen, Z.; Liu, T.; Gao, S.; Xie, J.; Ma, Q. Photosensitizer-encapsulated ferritins mediate photodynamic therapy against cancer-associated fibroblasts and improve tumor accumulation of nanoparticles. Mol. Pharm. 2018 , 15 , 3595−3599..

Han, H.; Hou, Y.; Chen, X.; Zhang, P.; Kang, M.; Jin, Q.; Ji, J.; Gao, M. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J. Am. Chem. Soc. 2020 , 142 , 4944−4954..

Wang, H.; Han, X.; Dong, Z.; Xu, J.; Wang, J.; Liu, Z. Hyaluronidase with pH-responsive dextran modification as an adjuvant nanomedicine for enhanced photodynamic-immunotherapy of cancer. Adv. Funct. Mater. 2019 , 29 , 1902440..

Hsieh, P. H.; Huang, W. Y.; Wang, H. C.; Kuan, C. H.; Shiue, T. Y.; Chen, Y.; Wang, T. W. Dual-re sponsive polypeptide nanoparticles attenuate tumor-associated stromal desmoplasia and anticancer through programmable dissociation. Biomaterials 2022 , 284 , 121469..

Shang, T.; Yu, X.; Han, S.; Yang, B. Nanomedicine-based tumor photothermal therapy synergized immunotherapy. Biomater. Sci. 2020 , 8 , 5241−5259..

Tan, T.; Hu, H.; Wang, H.; Li, J.; Wang, Z.; Wang, J.; Wang, S.; Zhang, Z.; Li, Y. Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles. Nat. Commun. 2019 , 10 , 3322..

Fang, T.; Zhang, J.; Zuo, T.; Wu, G.; Xu, Y.; Yang, Y.; Yang, J.; Shen, Q. Chemo-photothermal combination cancer therapy with ROS scavenging, extracellular matrix depletion, and tumor immune activation by telmisartan and diselenide-paclitaxel prodrug loaded nanoparticles. ACS Appl. Mater. Interfaces 2020 , 12 , 31292−31308..

Liu, Y.; Huo, Y.; Yao, L.; Xu, Y.; Meng, F.; Li, H.; Sun, K.; Zhou, G.; Kohane, D. S.; Tao, K. Transcytosis of nanomedicine for tumor penetration. Nano Lett. 2019 , 19 , 8010−8020..

Yan, Y.; Chen, B.; Wang, Z.; Yin, Q.; Wang, Y.; Wan, F.; Mo, Y.; Xu, B.; Zhang, Q.; Wang, S.; Wang, Y. Sequential modulations of tumor vasculature and stromal barriers augment the active targeting efficacy of antibody-modified nanophoto sensitizer in desmoplastic ovarian carcinoma. Adv. Sci. (Weinh) 2021 , 8 , 2002253..

Nagy, J. A.; Chang, S. H.; Shih, S. C.; Dvorak, A. M.; Dvorak, H. F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 2010 , 36 , 321−331..

Barua, S.; Mitragotri, S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 2014 , 9 , 223−243..

Luo, J.; Zhong, X.; Peng, Y.; Hao, C.; Liang, X.; Yang, Y.; Shi, X.; Chen, X.; Yi, X.; Li, X.; Wu, J.; Li, J.; Xiao, Q.; Wu, C.; Lu, R.; Pan, Y.; Wang, X.; Fan, J. B.; Wang, Y.; Wang, Y. Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics. Bioact. Mater. 2022 , 13 , 179−190..

Tang, Y.; Jia, C.; Wang, Y.; Wan, W.; Li, H.; Huang, G.; Zhang, X. Lactate consumption via cascaded enzymes combined VE GF siRNA for synergistic anti-proliferation and anti-angiogenesis therapy of tumors. Adv. Healthc. Mater. 2021 , 10 , e2100799..

Sun, C.; Gao, S.; Tan, Y.; Zhang, Z.; Xu, H. Side-chain selenium-grafted polymers combining antiangiogenesis treatment with photodynamic therapy and chemotherapy. ACS Biomater. Sci. Eng. 2021 , 7 , 3201−3208..

Li, S.; Zhang, Y.; Ho, S. H.; Li, B.; Wang, M.; Deng, X.; Yang, N.; Liu, G.; Lu, Z.; Xu, J.; Shi, Q.; Han, J. Y.; Zhang, L.; Wu, Y.; Zhao, Y.; Nie, G. Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nat. Biomed. Eng. 2020 , 4 , 732−742..

Bule, P.; Aguiar, S. I.; Aires-Da-Silva, F.; Dias, J. N. R. Chemokine-directed tumor microenvironment modulation in cancer immunotherapy. Int. J. Mol. Sci. 2021 , 22 , 9804..

Elsabahy, M.; Wooley, K. L. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem. Soc. Rev. 2013 , 42 , 5552−5576..

[Wang, Y.; Tiruthani, K.; Li, S.; Hu, M.; Zhong, G.; Tang, Y.; Roy, S.; Zhang, L.; Tan, J.; Liao, C.; Liu, R. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv. Mater . 2021 , 33 , e2007603..

Catalan, D.; Mansilla, M. A.; Ferrier, A.; Soto, L.; Oleinika, K.; Aguillon, J. C.; Aravena, O. Immunosuppressive mechanisms of regulatory B cells. Front. Immunol. 2021 , 12 , 611795..

Gao, S. H.; Liu, S. Z.; Wang, G. Z.; Zhou, G. B. CXCL13 in cancer and other diseases: Biological functions, clinical significance, and therapeutic opportunities. Life (Basel) 2021 , 11 , 1282..

Shen, L.; Li, J.; Liu, Q.; Das, M.; Song, W.; Zhang, X.; Tiruthani, K.; Dorosheva, O.; Hu, H.; Lai, S. K.; Liu, R.; Huang, L. Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth. J. Control. Release 2022 , 343 , 303−313..

Ren, X.; Cheng, Z.; He, J.; Yao, X.; Liu, Y.; Cai, K.; Li, M.; Hu, Y.; Luo, Z. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blocka de therapy in triple negative breast cancer. Nat. Commun. 2023 , 14 , 7021..

Chen, J.; Bu, C.; Lu, Y.; Peng, X.; Yu, J.; Ding, X.; Yuan, P.; Hong, S. Bioresponsive nanoreactor initiates cascade reactions for tumor vascular normalization and lactate depletion to augment immunotherapy. Biomaterials 2025 , 317 , 123100..

Guo, X.; Chen, X.; Ding, J.; Zhang, F.; Chen, S.; Hu, X.; Fang, S.; Shen, L.; Lu, C.; Zhao, Z.; Tu, J.; Shu, G.; Chen, M.; Ji, J. Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy. Asian J. Pharm. Sci. 2024 , 19 , 100905..

Hamouda, A. E. I.; Filtjens, J.; Brabants, E.; Kancheva, D.; Debraekeleer, A.; Brughmans, J.; Jacobs, L.; Bardet, P. M. R.; Knetemann, E.; Lefesvre, P.; Allonsius, L.; Gontsarik, M.; Varela, I.; Crabbé, M.; Clappaert, E. J.; Cappellesso, F.; Caro, A. A.; Gordún Peiró, A.; Fredericq, L.; Hadadi, E.; Estapé Senti, M.; Schiffelers, R.; van Grunsven, L. A.; Aboubakar Nana, F.; De Geest, B. G.; Deschoemaeker, S.; De Koker, S.; Lambolez, F.; Laoui, D. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun. 2024 , 15 , 10653..

Portale, F.; Carriero, R.; Iovino, M.; Kunderfranco, P.; Pandini, M.; Marelli, G.; Morina, N.; Lazzeri, M.; Casale, P.; Colombo, P.; De Simone, G.; Camisaschi, C.; Lugli, E.; Basso, G.; Cibella, J.; Marchini, S.; Bordi, M.; Meregalli, G.; Garbin, A.; Dambra, M.; Magrini, E.; Rackwitz, W.; Cecconi, F.; Corbelli, A.; Fiordaliso, F.; Eitler, J.; Tonn, T.; Di Mitri, D. C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer. Nat. Commun. 2024 , 15 , 10343..

Cao, C.; Xu, M.; Wei, Y.; Peng, T.; Lin, S.; Liu, X.; Xu, Y.; Chu, T.; Liu, S.; Wu, P.; Hu, B.; Ding, W.; Li, L.; Ma, D.; Wu, P. CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell Genomics 2024 , 4 , 100659..

Zhou, D.; Shao, L.; Spitz, D. R. Reactive oxygen species in normal and tumor stem cells. Adv. Cancer Res. 2014 , 122 , 1−67..

Schiliro, C.; Firestein, B. L. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 2021 , 10 , 1056..

Arlauckas, S. P.; Garren, S. B.; Garris, C. S.; Kohler, R. H.; Oh, J.; Pittet, M. J.; Weissleder, R. ARG1 expression defines immunosuppressive subsets of tumor- associated macrophages. Theranostics 2018 , 8 , 5842−5854..

Tian, L. R.; Lin, M. Z.; Zhong, H. H.; Cai, Y. J.; Li, B.; Xiao, Z. C.; Shuai, X. T. Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Biomater. Sci. 2022 , 10 , 3892−3900..

Choi, H.; Yeo, M.; Kang, Y.; Kim, H. J.; Park, S. G.; Jang, E.; Park, S. H.; Kim, E.; Kang, S. Lactate oxidase/catalase-displaying nanoparticles efficiently consume lactate in the tumor microenvironment to effectively suppress tumor growth. J. Nanobiotechnol. 2023 , 21 , 5..

Wei, D.; Cheng, X.; Du, C.; Wang, Y.; Sun, J.; Li, C.; Wu, J.; Tian, X.; Zhao, Y.; Nie, G.; Yang, Y. Stroma-targeted nanoparticles that remodel stromal alignment to enhance drug delivery and improve the antitumor efficacy of nab-paclitaxel in pancreatic ductal adenocarcinoma models. Nano Today 2022 , 45 , 101533..

Tan, H. Y.; Wang, N.; Li, S.; Hong, M.; Wang, X.; Feng, Y. The reactive oxygen species in macrophage polarization: Reflecting its dual role in progression and treatment of human diseases. Oxid. Med. Cell. Longev. 2016 , 2016 , 2795090..

Sang, Y.; Deng, Q.; Cao, F.; Liu, Z.; You, Y.; Liu, H.; Ren, J.; Qu, X. Remodeling macrophages by an iron nanotrap for tumor growth suppression. ACS Nano 2021 , 15 , 19298−19309..

Liu, Q.; Shi, L.; Liao, Y.; Cao, X.; Liu, X.; Yu, Y.; Wang, Z.; Lu, X.; Wang, J. Ultrathin-FeOOH-coated MnO 2 sonosensitizers with boosted reactive oxygen species yield and remodeled tumor microenvironment for efficient cancer therapy. Adv. Sci. 2022 , 9 , 2200005..

Dong, Z.; Wang, C.; Gong, Y.; Zhang, Y.; Fan, Q.; Hao, Y.; Li, Q.; Wu, Y.; Zhong, X.; Yang, K.; Feng, L.; Liu, Z. Chemical modulation of glucose metabolism with a fluorinated CaCO 3 nanoregulator can potentiate radiotherapy by programming antitumor immunity. ACS Nano 2022 , 16 , 13884−13899..

Wu, J.; Chen, J.; Feng, Y.; Zhang, S.; Lin, L.; Guo, Z.; Sun, P.; Xu, C.; Tian, H.; Chen, X. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci. Adv. 2020 , 6 , eabc7828..

Wu, J .; Guo, Z.; Ni, W.; Feng, Y.; Guo, X.; Meng, M.; Yuan, Y.; Lin, L.; Chen, J.; Tian, H.; Chen, X. Novel cocktail therapy based on a nanocarrier with an efficient transcytosis property reverses the dynamically deteriorating tumor microenvironment for enhanced immunotherapy. Nano Lett. 2022 , 22 , 7220−7229..

Feng, Y.; Wu, J.; Chen, J.; Lin, L.; Zhang, S.; Yang, Z.; Sun, P.; Li, Y.; Tian, H.; Chen, X. Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy. Nano Today 2021 , 38 , 101194..

Fang, H.; Chen, J.; Lin, L.; Liu, F.; Tian, H.; Chen, X. A strategy of killing three birds with one stone for cancer therapy through regulating the tumor microenvironment by H2O2-responsive gene delivery system. ACS Appl. Mater. Interfaces 2019 , 11 , 47785−47797..

Liu, S.; Wu, J.; Feng, Y.; Guo, X.; Li, T.; Meng, M.; Chen, J.; Chen, D.; Tian, H. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy. Bioact. Mater. 2023 , 22 , 211−224..

Zhang, S.; Zhang, Y.; Feng, Y.; Wu, J.; Hu, Y.; Lin, L.; Xu, C.; C hen, J.; Tang, Z.; Tian, H.; Chen, X. Biomineralized two-enzyme nanoparticles regulate tumor glycometabolism inducing tumor cell pyroptosis and robust antitumor immunotherapy. Adv. Mater. 2022 , 34 , e2206851..

Huang, J.; Zhuang, C.; Chen, J.; Chen, X.; Li, X.; Zhang, T.; Wang, B.; Feng, Q.; Zheng, X.; Gong, M.; Gong, Q.; Xiao, K.; Luo, K.; Li, W. Targeted drug/gene/photodynamic therapy via a stimuli-responsive dendritic-polymer-based nanococktail for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Adv. Mater. 2022 , 34 , e2201516..

Yu, C.; Liang, C.; Tao, H.; Du, Y.; Wu, D.; Dong, Z.; Jin, Q.; Chen, G.; Xu, J.; Xiao, Z.; Chen, Q.; Wang, C.; Chen, J.; Liu, Z. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci. Adv. 2020 , 6 , eaaz4204..

Wang, Z.; Wang, Q.; Cao, H.; Wang, Z.; Wang, D.; Liu, J.; Gao, T.; Ren, C.; Liu, J. Mitochondrial localized in situ self-assembly reprogramming tumor immune and metabolic microenvironment for enhanced cancer therapy. Adv. Mater. 2024 , 36 , 2311043..

Luo, H.; Lv, J.; Wen, P.; Zhang, S.; Ma, W.; Yang, Z. Supramolecular pol yrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy. Nat. Commun. 2025 , 16 , 2331..

An, J. X.; Qin, Y. T.; Tang, Y.; He, J. L.; Zhang, C.; Rao, Z. Y.; Xie, T. Q.; Zhang, X. Z. Polymerization of L-arginine into nanomicelles for immunometabolic engineering of adoptive macrophages in solid tumor therapy. Angew. Chem. Int. Ed. 2025 , 64 , e202507476..

Ying, W.; Zheng, C.; Gong, C.; Yuan, J.; Xu, G.; Zhou, J.; Fan, C.; Zhang, Y.; Luo, J.; Dan, R.; Huang, Y.; Li, X.; Chen, W.; Zhang, K.; Xing, M.; Wang, L.; Wang, H.; Yang, S.; Luo, Q. Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy. Nat. Nanotechnol. 2025 , 21 , 156−167..

Gulzar, A.; Xu, J.; Wang, C.; He, F.; Yang, D.; Gai, S.; Yang, P.; Lin, J.; Jin, D.; Xing, B. Tumour microenvironment responsive nanoconstructs for cancer theranostic. Nano Today 2019 , 26 , 16−56..

Cho, H.; Kwon, H. Y.; Sharma, A.; Lee, S. H.; Liu, X.; Miyamoto, N.; Kim, J. J.; Im, S. H.; Kang, N. Y.; Chang, Y. T. Visualizing inflammation with an M1 macrophage selective probe via GLUT1 as the gating target. Nat. Commun. 2022 , 13 , 5974..

Yang, X.; Zhao, M.; Wu, Z.; Chen, C.; Zhang, Y.; Wang, L.; Guo, Q.; Wang, Q.; Liang, S.; Hu, S.; Duan, Y.; Sun, Y. Nano-ultrasonic contrast agent for chemoimmunotherapy of breast cancer by immune metabolism reprogramming and tumor autophagy. ACS Nano 2022 , 16 , 3417−3431..

Hong, G.; Antaris, A. L.; Dai, H. Near-infrared fluorophores for biomedical imaging. Nat. Biomed. Eng. 2017 , 1 , 0010..

Sun, Y.; Ding, F.; Zhou, Z.; Li, C.; Pu, M.; Xu, Y.; Zhan, Y.; Lu, X.; Li, H.; Yang, G.; Sun, Y.; Stang, P. J. Rhomboidal Pt (II) metallacycle-based NIR-II theranostic nanoprobe for tumor diagnosis and image-guided therapy. Proc. Natl. Acad. Sci. U. S. A. 2019 , 116 , 1968−1973..

Wang, Z.; Ding, T.; Wang, L.; Wang, S.; Zhou, M.; Zhang, J.; Cai, K. Exo/endogenous factors co-activatable nanodevice for spatiotemporally controlled miRNA imaging and guided tumor ablation. Nano Res. 2021 , 15 , 845−857..

He, S.; Li, J.; Lyu, Y.; Huang, J.; Pu, K. Near-infrared fluorescent macromolecular reporte rs for real-time imaging and urinalysis of cancer immunotherapy. J. Am. Chem. Soc. 2020 , 142 , 7075−7082..

He, S.; Cheng, P.; Pu, K. Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. Nat. Biomed. Eng. 2023 , 7 , 281−297..

Belikov, A. V.; Schraven, B.; Simeoni, L. T cells and reactive oxygen species. J. Biomed. Sci. 2015 , 22 , 85..

Shi, C.; Zhang, Q.; Yao, Y.; Zeng, F.; Du, C.; Nijiati, S.; Wen, X.; Zhang, X.; Yang, H.; Chen, H.; Guo, Z.; Zhang, X.; Gao, J.; Guo, W.; Chen, X.; Zhou, Z. Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics. Nat. Nanotechnol. 2022 , 18 , 86−97..